Physician
Internal Medicine
Dr. Omer J. Iqbal, MD
|
|
Give Review
Omer Iqbal is an expert in the field of Internal Medicine. He attended Mount Sinai School of Medicine. He received 1 awards: "Fellow (FACC)". Omer J. Iqbal, MD is a published doctor. He has 68 papers published. The most current publication "Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes." He is registered with Medicare.
Publications
- A safe, simple technique for transseptal catheterization.
- Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD.
- Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product.
- Increased Expression of Secreted Frizzled-Related Protein-1 and Microtubule-Associated Protein Light Chain 3 in Keratoconus.
- Reference ranges of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited.
- Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3.
- Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.
- Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited.
- Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology.
- Pharmacogenomics in anticoagulant drug development.
- Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
- Air travel-associated venous thromboembolism.
- Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
- Practical issues in the development of argatroban: a perspective.
- Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
- Antiplatelet, anticoagulant, and thrombolytic drug interactions.
- Tissue factor pathway inhibitor in thrombosis and beyond.
- A survey of venous thrombosis models.
- Pharmacogenomics and coagulation disorders.
- Acute myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor.
- Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
- Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
- Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants.
- Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
- Antithrombotic agents in the treatment of severe sepsis.
- Pharmacogenomics and pharmacogenetics. 1st Spanish Congress on Pharmacogenomics and Pharmacogenetics, January 23-25, 2005, Valencia, Spain.
- Generic low molecular weight heparins: a significant dilemma.
- Clinical applications of bioinformatics, genomics, and pharmacogenomics.
- Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis.
- Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
- Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
- Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
- Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospe...
- European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats.
- Relative purity of different bovine thrombin preparations.
- Pro-inflammatory biomakers in depression: treatment with venlafaxine.
- Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
- Contaminant in the recalled unfractionated heparin preparations: where is the problem?
- Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
- Differential roles of T-cell subsets in regulation of ultraviolet radiation induced cutaneous photocarcinogenesis.
- Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated cho...
- Influence of different anticoagulant agents on fibrinopeptide a generation.
- A consensus conference on complex biologics and low molecular weight heparins.
- Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
- Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery ...
- Comparative tissue factor pathway inhibitor release potential of heparins.
- Emerging anticoagulant and thrombolytic drugs.
- Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathoph...
- Bleeding complications with glycoprotein IIb/IIIa inhibitors.
- Preclinical studies on a low molecular weight heparin.
- Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings.
- Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
- Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin.
- Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.
- Coagulation laboratory testing in patients treated with argatroban.
- Brain attack: who will write the orders for thrombolytics?
- Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods.
- Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications.
- Thrombolytic drugs in acute myocardial infarction.
- Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.
- Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test.
- Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
- Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.
- Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I.
- Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications.
- Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88).
- Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture.
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Fellow (FACC)
Education
-
University of Iowa Hospitals and Clinics -
Mount Sinai School of Medicine -
Allama Iqbal Medical College
Drug Facts
| NPI NUMBER | 1386807824 | |
| NPPES Provider LastName | IQBAL | |
| NPPES Provider FirstName | OMER | |
| NPPES Provider ZIPCode | 522421009 | |
| NPPES Provider State | IA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 59.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1386807824 |
| Last Name Of The Provider | IQBAL |
| First Name Of The Provider | OMER |
| View All |
Similar Doctors
|
|
Dr. Chris Watts, MD |
|
|
Dr. Scott R. Wilson, DO |
|
|
Dr. Martin O. Bazelak, MD |
|
|
Dr. Aparna S. Kamath, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah A. O'Shea, MD |
|
|
Dr. Vijay R. Pottathil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole E. Worden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine K. Schwab, MD |
|
|
Dr. Belal O. Al Khiami, MD |